Genentech

AntlerA Therapies is a regenerative medicine startup that is working on protein therapeutics that modulate developmental signaling pathways while also mobilizing tissue stem cell activity to enable endogenous tissue repair. They generated powerful antibody-like molecules (ANTs) that activate certain Frizzed receptor complexes using their unique protein engineering platform.

The 15 White Coats is a dynamic non-profit organization whose aim is to improve diversity in the medical sector by giving scholarships, mentorship, and support to underrepresented students pursuing medical degrees.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, founded in 2007. The company specializes in developing T cell therapies aimed at treating cancer, human immunodeficiency virus, and infectious diseases. Adaptimmune employs a proprietary platform that allows it to identify cancer targets, engineer T-cell receptors, and produce therapeutic candidates for patient administration. Its innovative approach strengthens patient T cell responses through the use of affinity T cell receptor proteins to target and eliminate cancerous or infected cells. The company’s therapeutic programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell therapy, and CD70, among others, addressing various cancer types.

Jecure Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Established in 2015 and operating as a subsidiary of Genentech, Inc. since 2018, the company specializes in innovative drug discovery programs aimed at addressing serious inflammatory diseases. Jecure's therapeutics work by blocking inflammasome activation and disrupting the inflammation processes that lead to liver cell injury and death. The company utilizes advanced methodologies, including SiRNA-based murine fibrosis models for target identification and validation, as well as unique in-vivo screening models that replicate key features of NASH. This approach enables the identification of drug candidates capable of intervening throughout the disease progression, facilitating a clearer path for translational development.

Seragon Pharmaceuticals, Inc., based in Irvine, California, is a research-focused biopharmaceutical company dedicated to enhancing human and animal health through innovative scientific advancements. The company specializes in the development of orally active selective estrogen receptor degraders (SERDs), particularly targeting metastatic breast cancer. Its lead drug candidate, ARN-810, is currently under evaluation for the treatment of estrogen receptor-positive breast cancer. By leveraging cutting-edge research in metabolism, gene therapy, and bioinformatics, Seragon Pharmaceuticals aims to facilitate access to significant medical breakthroughs, encompassing both clinical applications and consumer products.

RQx Pharmaceuticals, Inc., a biopharmaceutical company, develops broad spectrum antibiotics. The company was founded in 2010 and is based in La Jolla, California.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, the company is advancing several clinical-stage candidates, including CA-4948, an oral small molecule currently undergoing Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia. Other notable candidates in its pipeline include CI-8993, a monoclonal antibody targeting T cell activation, and Fimepinostat, a dual inhibitor for MYC-altered diffuse large B-cell lymphoma. Additionally, Curis is developing CA-170 for advanced solid tumors and CA-327, which is in pre-investigational stages. The company has established collaborations with leading organizations, including F. Hoffmann-La Roche and Genentech for the commercialization of Erivedge, a treatment for advanced basal cell carcinoma, and Aurigene Discovery Technologies for advancing small molecule compounds in immuno-oncology and precision oncology. Curis aims to leverage its expertise in signaling pathway drug technologies to create targeted therapies that address unmet medical needs in cancer treatment.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, the company is advancing several clinical-stage candidates, including CA-4948, an oral small molecule currently undergoing Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia. Other notable candidates in its pipeline include CI-8993, a monoclonal antibody targeting T cell activation, and Fimepinostat, a dual inhibitor for MYC-altered diffuse large B-cell lymphoma. Additionally, Curis is developing CA-170 for advanced solid tumors and CA-327, which is in pre-investigational stages. The company has established collaborations with leading organizations, including F. Hoffmann-La Roche and Genentech for the commercialization of Erivedge, a treatment for advanced basal cell carcinoma, and Aurigene Discovery Technologies for advancing small molecule compounds in immuno-oncology and precision oncology. Curis aims to leverage its expertise in signaling pathway drug technologies to create targeted therapies that address unmet medical needs in cancer treatment.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Tanox, Inc. is a a biotechnology company, engages in the discovery and development of therapeutic monoclonal antibodies.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.